FAQs – Frequently Asked Questions

  1. When could patients expect NephroDI’s NDI therapy to be available on the market?
    The therapy for nephrogenic diabetes insipidus (NDI) currently being developed by NephroDI still needs to meet several key milestones in clinical drug development and receive approval from pharmaceutical regulatory bodies (i.e. FDA) before it would be available to patients. This process could take until 2027 or longer if successful.  Interested parties are encouraged to check this website periodically for updated information.
  2. For which NDI patients would the therapy be applicable?
    NephroDI proposes to initially develop its first product to address X-linked NDI caused by a mutation on the vasopressin V2 receptor (AVPR2) gene. Based on preclinical studies, the first product is unlikely to be effective for congenital NDI caused by mutations on the aquaporin-2 (AQP2) gene. The effectiveness of this therapy on other forms of NDI is currently unknown.
  3. How can an X-linked NDI patient enroll or be enrolled in a potential clinical trial for this therapeutic?
    Human clinical trials for the NephroDI’s drug candidate are planned but have not yet been reviewed by the FDA or other regulatory agencies.  Additional details will be provided at this site when human clinical trials commence.  To be informed when clinical trials commence, please send an email to info@nephrodi.com